VTVT

+ Watchlist + Portfolio

vTv Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $32.90
52-Week Range: $14.55 – $44.00
Market Cap: $130.80M
P/E (TTM): —
EPS (TTM): -0.75
Dividend Yield: —

Advanced Metrics

Price/Book: 5.22
PEG Ratio: —
Return on Equity: -15.80%
Return on Assets: -10.14%
Gross Margin: 22.16%
Operating Margin: -25.11%
Profit Margin: -12.91%
Current Ratio: 12.48
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $674.38K
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $324.36M

VTVT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.02M	$0.00	$1.02M	$0.00
Research & Development	$12.36M	$13.60M	$11.55M	$17.86M
Selling, General & Admin	$12.20M	$11.91M	$13.65M	$14.95M
Operating Expenses	$24.56M	$25.50M	$25.20M	$32.81M
Operating Income	-$22.54M	-$25.50M	-$24.18M	-$32.81M
EBITDA	-$24.77M	-$25.86M	-$22.52M	-$31.06M
Pretax Income	-$24.87M	-$25.97M	-$22.61M	-$31.08M
Income Tax	$200.00K	$0.00	$100.00K	$0.00
Net Income	-$19.16M	-$20.25M	-$18.46M	-$26.97M
Diluted EPS	-10.40	-9.71	-3.20	-3.20
Diluted Shares	1.87M	2.08M	5.77M	8.42M

VTVT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.13M	$9.45M	$36.75M	$88.93M
Receivables	$12.42M	$102.00K	$62.00K	—
Current Assets	$27.09M	$10.66M	$38.11M	$89.89M
Total Assets	$33.24M	$11.02M	$38.27M	$89.90M
Current Liabilities	$7.71M	$10.62M	$5.20M	$6.64M
Total Debt	$716.00K	$529.00K	$169.00K	$0.00
Total Liabilities	$27.40M	$29.57M	$23.96M	$25.46M
Retained Earnings	-$265.52M	-$281.04M	-$299.72M	-$326.69M
Shareholders' Equity	-$10.74M	-$24.68M	$12.20M	$64.44M
Working Capital	$19.39M	$38.00K	$32.92M	$83.25M

VTVT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.02M	-$19.08M	-$25.31M	-$25.25M
Capital Expenditure	-$21.00K	—	—	—
Free Cash Flow	-$16.04M	-$19.08M	-$25.31M	-$25.25M
Depreciation & Amortisation	$92.00K	$90.00K	$89.00K	$16.00K
Stock-Based Compensation	$1.27M	$1.58M	$2.76M	$3.77M
Investing Cash Flow	-$21.00K	$4.40M	$0.00	$0.00
Financing Cash Flow	$14.75M	$12.00M	$52.61M	$77.44M
Net Change in Cash	-$1.29M	-$2.68M	$27.30M	$52.19M

VTVT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$36.84M
Research & Development	$2.83M	$4.10M	$7.02M	$3.91M	$8.98M
Selling, General & Admin	$3.67M	$3.62M	$3.68M	$3.98M	$4.60M
Operating Expenses	$6.50M	$7.72M	$10.70M	$7.88M	$13.58M
Operating Income	-$6.50M	-$7.72M	-$10.70M	-$7.88M	$23.26M
EBITDA	-$6.49M	-$7.72M	-$10.34M	-$7.13M	$23.26M
Pretax Income	-$6.22M	-$7.38M	-$10.35M	-$7.14M	$24.13M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$5.09M	-$6.05M	-$8.70M	-$7.14M	$24.13M
Diluted EPS	-0.77	-0.92	-1.08	-0.58	1.65
Diluted Shares	6.58M	6.59M	8.06M	12.41M	14.63M

VTVT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$31.06M	$25.92M	$98.50M	$88.93M	$98.09M
Current Assets	$31.92M	$26.37M	$99.46M	$89.89M	$98.81M
Total Assets	$32.03M	$26.45M	$99.49M	$89.90M	$98.81M
Current Liabilities	$4.32M	$5.29M	$10.16M	$6.64M	$6.88M
Total Debt	$125.00K	$79.00K	$360.00K	$0.00	—
Total Liabilities	$23.13M	$24.04M	$28.95M	$25.46M	$8.85M
Retained Earnings	-$304.81M	-$310.86M	-$319.55M	-$326.69M	-$302.56M
Shareholders' Equity	$7.92M	$2.76M	$70.54M	$64.44M	$89.96M
Working Capital	$27.60M	$21.08M	$89.29M	$83.25M	$91.93M

VTVT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.69M	-$5.09M	-$5.22M	-$9.25M	$9.15M
Free Cash Flow	-$5.69M	-$5.09M	-$5.22M	-$9.25M	$9.15M
Depreciation & Amortisation	$9.00K	$3.00K	$2.00K	$2.00K	$1.00K
Stock-Based Compensation	$813.00K	$930.00K	$1.01M	$1.02M	$1.39M
Financing Cash Flow	$0.00	-$42.00K	$77.80M	-$321.00K	—
Net Change in Cash	-$5.69M	-$5.14M	$72.58M	-$9.57M	$9.15M

Market Snapshot

About

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for metabolic diseases including type 2 diabetes and hypoglycemia. The company leverages its expertise in glucose metabolism to advance innovative oral therapies targeting unmet medical needs. vTv Therapeutics is advancing multiple drug candidates through various stages of clinical development.